Freya Bachmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Freya Bachmann has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Gilbert Koch
Pediatric Pharmacology and Pharmacometrics University Children's Hospital Basel UKBB Basel Switzerland
3 shared publications Johannes Schropp
Department of Mathematics and Statistics University of Konstanz Konstanz Germany
3 shared publicationsBritta Steffens
Pediatric Pharmacology and Pharmacometrics, University of Basel Children’s Hospital, Basel, Switzerland
2 shared publicationsGabor Szinnai
Pediatric Endocrinology and Diabetology, University of Basel Children’s Hospital, Basel, Switzerland
2 shared publicationsMarc Pfister
Pediatric Pharmacology and Pharmacometrics, University of Basel Children’s Hospital, Basel, Switzerland
2 shared publications- Marc Pfister
University Children’s Hospital Basel (UKBB), 4031 Basel, Switzerland
2 shared publications
Latest Publications
- Open Access
- 4 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2232-2243
Redefining Parameter Estimation and Covariate Selection via Variational Autoencoders: One Run Is All You Need
Generative Artificial Intelligence (AI) frameworks, such as Variational Autoencoders (VAEs), have proven powerful in learning structured representations from complex, high‐dimensional data. In pharmacometrics (PMX), nonlinear mixed effects (NLME) modeling is widely used to capture inter‐individual variability and link covariates to characterize parameters with the goal of informing key decisions in drug research and development. This research combines the strengths of both approaches by introducing a VAE framework specifically designed for NLME modeling. The proposed method integrates the flexibility of generative AI with the interpretability and robustness of mechanism‐based PMX modeling. To advance covariate selection in PMX, we replace the Evidence Lower Bound objective in VAEs with an objective function based on the corrected Bayesian information criterion. This enables the simultaneous evaluation of all potential covariate‐parameter combinations, thereby allowing for automated and joint estimation of population parameters and covariate selection within a single run. Manual selection and repeated model fitting across covariate combinations are no longer required. We demonstrate the effectiveness of this combined AI‐PMX approach with two representative cases. As the first generative AI‐based optimization method for NLME modeling, the VAE achieves high‐quality results in a single run, outperforming traditional stepwise procedures in terms of efficiency. As such, the presented approach facilitates automated model development, advancing PMX and its applications in model‐informed drug development.
- 4 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2232-2243
Open AccessRedefining Parameter Estimation and Covariate Selection via Variational Autoencoders: One Run Is All You Need
Generative Artificial Intelligence (AI) frameworks, such as Variational Autoencoders (VAEs), have proven powerful in learning structured representations from complex, high‐dimensional data. In pharmacometrics (PMX), nonlinear mixed effects (NLME) modeling is widely used to capture inter‐individual variability and link covariates to characterize parameters with the goal of informing key decisions in drug research and development. This research combines the strengths of both approaches by introducing a VAE framework specifically designed for NLME modeling. The proposed method integrates the flexibility of generative AI with the interpretability and robustness of mechanism‐based PMX modeling. To advance covariate selection in PMX, we replace the Evidence Lower Bound objective in VAEs with an objective function based on the corrected Bayesian information criterion. This enables the simultaneous evaluation of all potential covariate‐parameter combinations, thereby allowing for automated and joint estimation of population parameters and covariate selection within a single run. Manual selection and repeated model fitting across covariate combinations are no longer required. We demonstrate the effectiveness of this combined AI‐PMX approach with two representative cases. As the first generative AI‐based optimization method for NLME modeling, the VAE achieves high‐quality results in a single run, outperforming traditional stepwise procedures in terms of efficiency. As such, the presented approach facilitates automated model development, advancing PMX and its applications in model‐informed drug development.
- Open Access
- 8 October 2024
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 51 (6) , 919-934
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM
Recently, an optimal dosing algorithm (OptiDose) was developed to compute the optimal drug doses for any pharmacometrics model for a given dosing scenario. In the present work, we enhance the OptiDose concept to compute optimal drug dosing with respect to both efficacy and safety targets. Usually, these are not of equal importance, but one is a top priority, that needs to be satisfied, whereas the other is a secondary target and should be achieved as good as possible without failing the top priority target. Mathematically, this leads to state-constrained optimal control problems. In this paper, we elaborate how to set up such problems and transform them into classical unconstrained optimal control problems which can be solved in NONMEM. Three different optimal dosing tasks illustrate the impact of the proposed enhanced OptiDose method.
- 8 October 2024
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 51 (6) , 919-934
Open AccessComputing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM
Recently, an optimal dosing algorithm (OptiDose) was developed to compute the optimal drug doses for any pharmacometrics model for a given dosing scenario. In the present work, we enhance the OptiDose concept to compute optimal drug dosing with respect to both efficacy and safety targets. Usually, these are not of equal importance, but one is a top priority, that needs to be satisfied, whereas the other is a secondary target and should be achieved as good as possible without failing the top priority target. Mathematically, this leads to state-constrained optimal control problems. In this paper, we elaborate how to set up such problems and transform them into classical unconstrained optimal control problems which can be solved in NONMEM. Three different optimal dosing tasks illustrate the impact of the proposed enhanced OptiDose method.
- Open Access
- 30 January 2024
- Published by Springer Nature in Research Square
Computing optimal drug dosing regarding efficacy and safety - the enhanced OptiDose method in NONMEM
Recently, an optimal dosing algorithm (OptiDose) was developed to compute the optimal drug doses for any pharmacometrics model for a given dosing scenario. In the present work, we enhance the OptiDose concept to compute optimal drug dosing with respect to both efficacy and safety targets. Usually, these are not of equal importance, but one is a top priority, that needs to be satisfied, whereas the other is a secondary target and should be achieved as good as possible without failing the top priority target. Mathematically, this leads to state-constrained optimal control problems. In this paper, we elaborate how to set up such problems and transform them into classical unconstrained optimal control problems which can be solved in NONMEM. Three different optimal dosing tasks illustrate the impact of the proposed enhanced OptiDose method.
- 30 January 2024
- Published by Springer Nature in Research Square
Open AccessComputing optimal drug dosing regarding efficacy and safety - the enhanced OptiDose method in NONMEM
Recently, an optimal dosing algorithm (OptiDose) was developed to compute the optimal drug doses for any pharmacometrics model for a given dosing scenario. In the present work, we enhance the OptiDose concept to compute optimal drug dosing with respect to both efficacy and safety targets. Usually, these are not of equal importance, but one is a top priority, that needs to be satisfied, whereas the other is a secondary target and should be achieved as good as possible without failing the top priority target. Mathematically, this leads to state-constrained optimal control problems. In this paper, we elaborate how to set up such problems and transform them into classical unconstrained optimal control problems which can be solved in NONMEM. Three different optimal dosing tasks illustrate the impact of the proposed enhanced OptiDose method.
- Open Access
- 24 February 2021
- Published by Springer Nature in Journal of Optimization Theory and Applications
- Vol. 189 (1) , 46-65
OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
Providing the optimal dosing strategy of a drug for an individual patient is an important task in pharmaceutical sciences and daily clinical application. We developed and validated an optimal dosing algorithm (OptiDose) that computes the optimal individualized dosing regimen for pharmacokinetic–pharmacodynamic models in substantially different scenarios with various routes of administration by solving an optimal control problem. The aim is to compute a control that brings the underlying system as closely as possible to a desired reference function by minimizing a cost functional. In pharmacokinetic–pharmacodynamic modeling, the controls are the administered doses and the reference function can be the disease progression. Drug administration at certain time points provides a finite number of discrete controls, the drug doses, determining the drug concentration and its effect on the disease progression. Consequently, rewriting the cost functional gives a finite-dimensional optimal control problem depending only on the doses. Adjoint techniques allow to compute the gradient of the cost functional efficiently. This admits to solve the optimal control problem with robust algorithms such as quasi-Newton methods from finite-dimensional optimization. OptiDose is applied to three relevant but substantially different pharmacokinetic–pharmacodynamic examples.
- 24 February 2021
- Published by Springer Nature in Journal of Optimization Theory and Applications
- Vol. 189 (1) , 46-65
Open AccessOptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
Providing the optimal dosing strategy of a drug for an individual patient is an important task in pharmaceutical sciences and daily clinical application. We developed and validated an optimal dosing algorithm (OptiDose) that computes the optimal individualized dosing regimen for pharmacokinetic–pharmacodynamic models in substantially different scenarios with various routes of administration by solving an optimal control problem. The aim is to compute a control that brings the underlying system as closely as possible to a desired reference function by minimizing a cost functional. In pharmacokinetic–pharmacodynamic modeling, the controls are the administered doses and the reference function can be the disease progression. Drug administration at certain time points provides a finite number of discrete controls, the drug doses, determining the drug concentration and its effect on the disease progression. Consequently, rewriting the cost functional gives a finite-dimensional optimal control problem depending only on the doses. Adjoint techniques allow to compute the gradient of the cost functional efficiently. This admits to solve the optimal control problem with robust algorithms such as quasi-Newton methods from finite-dimensional optimization. OptiDose is applied to three relevant but substantially different pharmacokinetic–pharmacodynamic examples.